Pharmacologic strategies in the prevention and treatment of corneal transplant rejection

International Ophthalmology

Volumn 28, Issue 3, 2008, Pages 223-232

  Tabbara, Khalid F ^a  

^a The Eye Foundation for Research in Ophthalmology   (Saudi Arabia)

Author keywords

Allograft; Autograft; Corneal; Corticosteroids; Graft rejection; Transplantation

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CALCIUM; CIDOFOVIR; CORTICOSTEROID; CYCLOPENTOLATE; CYCLOSPORIN; DACLIZUMAB; FAMCICLOVIR; GANCICLOVIR; HLA A ANTIGEN; HLA B ANTIGEN; HOMATROPINE; IDOXURIDINE; LEFLUNOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISOLONE ACETATE; RAPAMYCIN; TACROLIMUS; TRIAMCINOLONE ACETATE; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; VIDARABINE; VIRGAN; VITAMIN D;

ARTICLE; BEDTIME DOSAGE; CLINICAL FEATURE; CONGENITAL CORNEA DYSTROPHY; CORNEA DISEASE; CORNEA EDEMA; CORNEA OPACITY; CORNEA PRESERVATION; CORNEA TRANSPLANTATION; CORNEA VASCULARIZATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TISSUE LEVEL; EARLY DIAGNOSIS; EYE DISEASE; GRAFT PRESERVATION; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HERPES SIMPLEX KERATITIS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INCIDENCE; KERATOCONUS; LOW DRUG DOSE; MICROSURGERY; OSTEOPOROSIS; PENETRATING KERATOPLASTY; PHARMACEUTICAL CARE; PREOPERATIVE EVALUATION; PRIMARY PREVENTION; RISK FACTOR; SURGICAL EQUIPMENT; SURGICAL RISK; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; CORNEAL TRANSPLANTATION; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 43049123833     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-007-9100-7     Document Type: Article

References (43)

1. Beckingsale P, Mavrikakis I, Al-Yousuf N, Mavrikakis E, Daya SM (2006) Penetrating keratoplasty: Outcomes from a corneal unit compared to national data. Br J Ophthalmol 90(6):728-731
2. Sangwan VS, Ramamurthy B, Shah U, Garg P, Sridhar MS, Rao GN (2005) Outcome of corneal transplant rejection: A 10 year study. Clin Exp Ophthalmol 33(6):623-627
3. Afshari NA, Pittard AB, Siddiqui A, Klintworth GK (2006) Clinical study of Fuchs corneal endothelial dystrophy leading to penetrating keratoplasty: A 30-year experience. Arch Ophthalmol 124(6):777-780
4. Al-Hazzaa S, Tabbara KF (1988) Bacterial keratitis after penetrating keratoplasty. Ophthalmology 95(11):1504-1508
5. Al-Faran MF, Tabbara KF (1991) Corneal dystrophies among patients undergoing penetrating keratoplasty. Cornea 10(1):13-16
6. Al-Towerki A, Al-Rajhi AA, Wagoner MD (2004) Changing indications for keratoplasty at the King Khaled Eye Specialist Hospital (1983-2002). Cornea 23(6):584-588
7. Al-Swailem SA, Al-Rajhi AA, Wagoner MD (2005) Penetrating keratoplasty for macular corneal dystrophy. Ophthalmology 112(2):220-224
8. Randleman JB, Stulting RD (2006) Prevention and treatment of corneal graft rejection: Current practice patterns (2004). Cornea 25(3):286-290
9. Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ (2006) How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 81(6):896-901
10. Javadi MA, Motlagh BF, Jafarinasab MR, Rabbanikhah Z, Anissian A, Souri H, Yazdani S (2005) Outcomes of penetrating keratoplasty in keratoconus. Cornea 24(8):941-946
11. Dua HS, Azuara-Blanco A (1999) Corneal allograft rejection: Risk factors, diagnosis, prevention and treatment [review]. Indian J Ophthalmol 47(1):3-9
12. Niederkorn JY, Stevens C, Mellon J, Mayhew E (2006) CD4+ T-cell independent rejection of corneal allografts. Transplantation 81(8):1171-1178
13. Yamagami S, Hamrah P, Zhang Q, Liu Y, Huq S, Dana MR (2005) Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Mol Vis 11:632-640
14. Nicholls SM, Banerjee S, Figueiredo FC, Crome S, Mistry S, Easty DL, Dick AD (2006) Differences in leukocyte phenotype and interferon-gamma expression in stroma and endothelium during corneal graft rejection. Exp Eye Res 83(2):339-347
15. Watson SL, Tuft SJ, Dart JK (2006) Patterns of rejection after deep lamellar keratoplasty. Ophthalmology 113(4):556-560
16. Niederkorn JY, Stevens C, Mellon J, Mayhew E (2006) Differential roles of CD8+ and CD8-T lymphocytes in corneal allograft rejection in "high-risk" hosts. Am J Transplant 6(4):705-713
17. Frost NA, Wu J, Lai TF, Coster DJ (2006) A review of randomized controlled trials of penetrating keratoplasty techniques. Ophthalmology 113(6):942-949
18. Collaborative Corneal Transplantation Studies Research Group (1992) Effectiveness of histocompatibility matching in high risk corneal transplantation. Arch Ophthalmol 110:1392-1403
19. Volker-Dieben HJ, Kok-van Alphen CC, Krut PJ (1979) Advances and disappointments, indications and restrictions regarding HLA matched corneal grafts in high risk cases. Doc Ophthalmol 46:219-226
20. Volker-Dieben HJ, Kok-van Alphen CC, Lansbergen Q, Persijn GG (1982) The effect of prospective HLA-A and -B matching on corneal graft survival. Acta Ophthalmol 60:203-212
21. Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN (1986) Reduced graft rejection with good HLA-A and HLA-B matching in high risk corneal transplantation. N Engl J Med 315:29-35
22. Price MO, Price FW Jr (2006) Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology 113(10):1785-1790
23. Reed MH, Shapiro ME, Strom TB et al (1989) Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 47:55-59
24. Brown PS Jr, Parentean GL, Dirbas FM et al (1991) Anti-Tac-H, a humanized antibody to interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88:2663-2667
25. Wihelmus KR (2000) The treatment of herpes simplex virus epithelial keratitis. Trans Am Ophthalmol Soc 98:505-532
26. Hyndiuk R, Glasser D (1996) Herpes simplex keratitis. In: Tabbara KF, Hyndiuk R (eds) Infections of the eye, 2nd edn. Little, Brown, Boston, pp 361-386
27. O'Brien W (1996) Antiviral agents. In: Tabbara K, Hyndiuk R (eds) Infections of the eye, 2nd edn. Little, Brown, Boston, pp 269-280
28. Davies ME, Bondi JV, Grabowski L et al (1987) 2′Nor-2′deoxyguanosine is an effective therapeutic agent for treatment of experimental herpes keratitis. Antiviral Res 7(2):119-125
29. Gordon YJ, Capone A, Sheppard J et al (1987) 2′-nor-cGMP, a new cyclic derivative of 2′NDG, inhibits HSV-1 replication in vitro and the mouse keratitis model. Curr Eye Res 6(1):247-253
30. Shiota H, Naito T, Mimura Y (1987) Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea. Curr Eye Res 6(1):241-245
31. Castela N, Vermerie N, Chast F et al (1994) Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: Intraocular penetration and efficacy. J Ocul Pharmacol 10(2):439-451
32. Colin J, Hoh HB, Easty DL et al (1997) Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 16(4):393-399
33. Hoh HB, Hurley C, Claoue C et al (1996) Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: A multicentre study. Br J Ophthalmol 80(2):140-143
34. Tabbara KF (2005) Treatment of herpetic keratitis. Ophthalmology 112(9):1640
35. Pouliquen P, Elena PP, Malecaze F et al (1996) Assessment of the safety and local pharmacokinetics of a 0.15% gel of ganciclovir (Virgan ®) in healthy volunteers. Invest Ophthalmol Vis Sci 37(3):S313
36. Shaw MM, Gurr WK, Watts PA et al (2001) Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinase-transformed baby hamster kidney cells. Antivir Chem Chemother 12(3):175-186
37. Epstein RJ, Seedor JA, Dreizen NG et al (1987) Penetrating keratoplasty for herpes simplex keratitis and keratoconus: Allograft rejection and survival. Ophthalmology 94(8):935-944
38. Ficker LA, Kirkness CM, Rice NS et al (1989) Changing management and improved prognosis for corneal grafting and herpes simplex keratitis. Ophthalmology 96(11):1587-1596
39. Sonkin PL, Baratz KH, Frothingham R et al (1992) Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty. Ophthalmology 99(12):1805-1808
40. Rapuano CJ, Cohen EJ, Brady SE et al (1990) Indications for and outcomes of repeat penetrating keratoplasty. Am J Ophthalmol 109(6):689-695
41. De Kesel RJ, Koppen C, Leven M et al (2001) Primary graft failure caused by herpes simplex virus type I. Cornea 20(2):187-190
42. Akova YA, Onat M, Duman S (1999) Efficacy of low dose and long term oral acyclovir therapy after penetrating keratoplasty for herpes simplex keratitis. Ocul Immunol Inflamm 7(1):51-60
43. Lairson DR, Begley CE, Wilhelmus KR (2003) Prevention of herpes simplex virus eye disease. A cost-effectiveness analysis. Arch Ophthalmol 121(1):108-112